Medical devices, healthcare technology and the business of care
510(k) clearance · K260738

Safe AQ Easy Blood Glucose Monitoring System; Safe AQ Care Blood Glucose Monitoring System

Changsha Sinocare, Inc. · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONK260738

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 30 October 2026 for K260738, covering the Safe AQ Easy Blood Glucose Monitoring System and the Safe AQ Care Blood Glucose Monitoring System submitted by Changsha Sinocare, Inc. of Changsha, Hunan, China. The application was received on 6 March 2026 and falls under regulation number 862.1345, product code NBW, in the Clinical Chemistry specialty and review panel.

SESE denotes 510(k) clearance rather than premarket approval. The public record lists no summary statement, so the specific device components, any changed items relative to a predicate device, and the basis for the equivalence determination are not described in the available material. The page also records that the submission was not reviewed by a third party, was not a combination product, and had no authorized predetermined change control plan.

Details of the cleared configurations, performance data and labeling remain outside this record and would need the underlying FDA decision documents.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Chemistry
Decision date
Oct 30, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260738
Regulatory pathway
510(k) premarket notification
Product code
NBW
Decision code
SESE
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Test, Blood Glucose, Over The Counter.

Product code
NBW
FDA device class
2

FDA decision timeline

  1. K260738 received

    Application receipt date recorded by FDA.

  2. K260738 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NBW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Changsha Sinocare, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Changsha, Hunan

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records